EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Effects of GLP ‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD : A Systematic Review

Fernando Iorra iD, Tanya Jayakar, Michael Yee, Mark R Thursz, Beatriz D Schaan, Pinelopi Manousou iD

Liver International · 2026-05 · 46 (5)

DOI: 10.1111/liv.70643 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Liver International, online erschienen am 17.04.2026. Verfasst von Fernando Iorra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Medical Sciences: Endocrinology, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Muscle Strength, Muscle, Skeletal, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims GLP‐1 receptor agonists (GLP‐1RAs) promote significant weight loss, but their impact on muscle mass, strength, and quality in metabolic dysfunction–associated steatotic liver disease (MASLD), a condition prone to muscle impairment, remains uncertain.

Methods

We conducted a systematic review of MEDLINE/PubMed, Embase, and the Cochrane Library up to 2 December 2025. Interventional and observational studies assessing GLP‐1RA therapy and muscle‐related outcomes in adults with MASLD were included. Muscle mass was assessed by computed tomography or magnetic resonance imaging, dual‐energy X‐ray absorptiometry, or bioelectrical impedance analysis; lean mass and fat‐free mass were considered proxies. Muscle strength was evaluated using handgrip strength (HGS) or sit‐to‐stand (STS) tests. Muscle quality was assessed by imaging‐based quantification of intramuscular fat infiltration (myosteatosis) or functionally based on performance relative to muscle mass. Results were synthesised narratively.

Results

Twelve studies were included ( n = 810). Eleven assessed muscle mass ( n = 785) across different GLP‐1RA regimens and treatment durations (12–52 weeks). Findings suggested relative preservation of muscle mass, with modest reductions generally proportional to overall weight loss. Muscle strength was evaluated in three studies ( n = 477), with no evidence of deterioration in HGS or STS performance despite meaningful weight loss. Muscle quality was assessed in four studies ( n = 139) using imaging or functional metrics, with results suggesting preserved or improved muscle quality. Evidence was limited by small sample sizes and heterogeneous assessment methods.

Conclusion

Current evidence suggests that GLP‐1RA therapy is not associated with clinically meaningful loss of muscle mass or strength in adults with MASLD, with early data indicating possible improvements in muscle quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsMuscle StrengthMuscle, SkeletalNon-alcoholic Fatty Liver DiseaseFatty LiverHumansHand Strength

Stichwörter der Autor:innen

glucagon‐like Peptide‐1 receptor agonistsmuscle strengthmusclesnon‐alcoholic fatty liver disease

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Postgraduate Program in Medical Sciences: Endocrinology, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
  • Faculty of Medicine, Imperial College London, London, UK.
  • Section of Endocrinology and Metabolic Medicine, St Mary's Hospital, Imperial College NHS Trust, London, UK.
  • Liver Unit/Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
  • Hospital De Clínicas De Porto Alegre, Porto Alegre, Brazil.

ORCID-Profile: Fernando Iorra, Pinelopi Manousou

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Iorra, F., Jayakar, T., Yee, M., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026). Effects of GLP ‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD : A Systematic Review. Liver International, 46(5). https://doi.org/10.1111/liv.70643

Vancouver

Iorra F, Jayakar T, Yee M, Thursz MR, Schaan BD, Manousou P. Effects of GLP ‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD : A Systematic Review. Liver International. 2026;46(5). doi:10.1111/liv.70643

BibTeX
@article{Iorra2026,
  author = {Iorra, Fernando and Jayakar, Tanya and Yee, Michael and Thursz, Mark R and Schaan, Beatriz D and Manousou, Pinelopi},
  title = {Effects of GLP ‐1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD : A Systematic Review},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {5},
  doi = {10.1111/liv.70643}
}
Kostenlos starten →